India, April 16 -- Bluebird bio, Inc. (BLUE), the Massachusetts based biotechnology company, on Wednesday announced that after three weeks of discussions and an extended deadline Ayrmid Ltd. has not made a formal acquisition offer and has not secured the required funding.
Bluebird said its Board has confirmed the acquisition offer by Carlyle Group, Inc. (CG) and SK Capital Partners, LP. The Board urged all shareholders to accept the current offer by May 2.
On February 21, the company had announced a definitive agreement to be acquired by funds managed by global investment firms Carlyle and SK, in collaboration with a team of highly experienced biotech executives.
Under the terms of the agreement, Bluebird stockholders would be receiving ...